Phase II study of a new alkylating agent (PTT-119) in resistant-relapsed non-Hodgkin's lymphomas

S. Tura; P. Mazza; F. Gherlinzoni; P. L. Zinzani; G. Poletti; G. Visani; R. M. Lemoli; M. Cavo; P. Galieni; C. Tassi; R. Zanchini

doi:10.1007/BF00273532

Phase II study of a new alkylating agent (PTT-119) in resistant-relapsed non-Hodgkin's lymphomas

S. Tura, P. Mazza, F. Gherlinzoni, P. L. Zinzani, G. Poletti, G. Visani, R. M. Lemoli, M. Cavo, P. Galieni, C. Tassi, R. Zanchini

A.O.U. San Martino - IST, Istituto Nazionale Ricerca sul Cancro (GENOVA)

Research output: Contribution to journal › Article › peer-review

Abstract

In a phase II study we evaluated the effect and toxicity of a new alkylating agent, PTT-119, in 26 patients with non-Hodgkin's lymphomas (NHL) resistant to or relapsed alter other chemotherapy. PTT was scheduled by ascalating the dose from 2.0 to 3.3 mg/kg every 3 weeks. Among 21 evaluable patients with NHL, 12 (57%) showed a good response (CR+PR) to PTT-119. Tolerance was acceptably good; no major side effects related to liver, cardiac, or renal toxicity were recorded. The most commonly recorded side effects were nausea and vomiting, alopecia, and phlebitis; diarrhea and drug-related fever were rarely seen. This report indicates a potential usefulness for PTT-119, a non-cross-resistant alkylating agent, in the treatment of NHL.

Original language	English
Pages (from-to)	123-125
Number of pages	3
Journal	Cancer Chemotherapy and Pharmacology
Volume	23
Issue number	2
DOIs	https://doi.org/10.1007/BF00273532
Publication status	Published - Feb 1989

ASJC Scopus subject areas

Pharmacology
Oncology
Cancer Research

Access to Document

10.1007/BF00273532

Cite this

Phase II study of a new alkylating agent (PTT-119) in resistant-relapsed non-Hodgkin's lymphomas. / Tura, S.; Mazza, P.; Gherlinzoni, F.; Zinzani, P. L.; Poletti, G.; Visani, G.; Lemoli, R. M.; Cavo, M.; Galieni, P.; Tassi, C.; Zanchini, R.

In: Cancer Chemotherapy and Pharmacology, Vol. 23, No. 2, 02.1989, p. 123-125.

Research output: Contribution to journal › Article › peer-review

@article{b66007d5796e4ddd85ab95aeb80249c1,

title = "Phase II study of a new alkylating agent (PTT-119) in resistant-relapsed non-Hodgkin's lymphomas",

abstract = "In a phase II study we evaluated the effect and toxicity of a new alkylating agent, PTT-119, in 26 patients with non-Hodgkin's lymphomas (NHL) resistant to or relapsed alter other chemotherapy. PTT was scheduled by ascalating the dose from 2.0 to 3.3 mg/kg every 3 weeks. Among 21 evaluable patients with NHL, 12 (57%) showed a good response (CR+PR) to PTT-119. Tolerance was acceptably good; no major side effects related to liver, cardiac, or renal toxicity were recorded. The most commonly recorded side effects were nausea and vomiting, alopecia, and phlebitis; diarrhea and drug-related fever were rarely seen. This report indicates a potential usefulness for PTT-119, a non-cross-resistant alkylating agent, in the treatment of NHL.",

author = "S. Tura and P. Mazza and F. Gherlinzoni and Zinzani, {P. L.} and G. Poletti and G. Visani and Lemoli, {R. M.} and M. Cavo and P. Galieni and C. Tassi and R. Zanchini",

year = "1989",

month = feb,

doi = "10.1007/BF00273532",

language = "English",

volume = "23",

pages = "123--125",

journal = "Cancer Chemotherapy and Pharmacology",

issn = "0344-5704",

publisher = "Springer Verlag",

number = "2",

}

TY - JOUR

T1 - Phase II study of a new alkylating agent (PTT-119) in resistant-relapsed non-Hodgkin's lymphomas

AU - Tura, S.

AU - Mazza, P.

AU - Gherlinzoni, F.

AU - Zinzani, P. L.

AU - Poletti, G.

AU - Visani, G.

AU - Lemoli, R. M.

AU - Cavo, M.

AU - Galieni, P.

AU - Tassi, C.

AU - Zanchini, R.

PY - 1989/2

Y1 - 1989/2

N2 - In a phase II study we evaluated the effect and toxicity of a new alkylating agent, PTT-119, in 26 patients with non-Hodgkin's lymphomas (NHL) resistant to or relapsed alter other chemotherapy. PTT was scheduled by ascalating the dose from 2.0 to 3.3 mg/kg every 3 weeks. Among 21 evaluable patients with NHL, 12 (57%) showed a good response (CR+PR) to PTT-119. Tolerance was acceptably good; no major side effects related to liver, cardiac, or renal toxicity were recorded. The most commonly recorded side effects were nausea and vomiting, alopecia, and phlebitis; diarrhea and drug-related fever were rarely seen. This report indicates a potential usefulness for PTT-119, a non-cross-resistant alkylating agent, in the treatment of NHL.

AB - In a phase II study we evaluated the effect and toxicity of a new alkylating agent, PTT-119, in 26 patients with non-Hodgkin's lymphomas (NHL) resistant to or relapsed alter other chemotherapy. PTT was scheduled by ascalating the dose from 2.0 to 3.3 mg/kg every 3 weeks. Among 21 evaluable patients with NHL, 12 (57%) showed a good response (CR+PR) to PTT-119. Tolerance was acceptably good; no major side effects related to liver, cardiac, or renal toxicity were recorded. The most commonly recorded side effects were nausea and vomiting, alopecia, and phlebitis; diarrhea and drug-related fever were rarely seen. This report indicates a potential usefulness for PTT-119, a non-cross-resistant alkylating agent, in the treatment of NHL.

UR - http://www.scopus.com/inward/record.url?scp=0024271402&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0024271402&partnerID=8YFLogxK

U2 - 10.1007/BF00273532

DO - 10.1007/BF00273532

M3 - Article

C2 - 2910510

AN - SCOPUS:0024271402

VL - 23

SP - 123

EP - 125

JO - Cancer Chemotherapy and Pharmacology

JF - Cancer Chemotherapy and Pharmacology

SN - 0344-5704

IS - 2

ER -

Phase II study of a new alkylating agent (PTT-119) in resistant-relapsed non-Hodgkin's lymphomas

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this